KDMN News and Press, Kadmon Holdings Inc. From 02/19/21

Kadmon's cGVHD asset is Belumosudil. The molecule has shown a strong efficacy profile. The company has a strong cash balance. For further details see: Kadmon Looks Highly Investable Before PDUFA

NEW YORK, NY / ACCESSWIRE / February 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualified institutional buyers pursuant to ...

Kadmon Holdings ([[KDMN]] -8.8%) has priced upsized $200M (from $150M) of 3.625% convertible senior unsecured notes due February 15, 2027 in a private offering.Initial purchaser granted an option to purchase up to an additional $40M of the notes.Offering is expected to close on February ...

Anchiano Therapeutics (ANCN) -28%.Pulmatrix (PULM) -21% on direct offering.United States Antimony (UAMY) -21% on direct offering.Cancer Genetics (CGIX) -21% on stock offering.BioHiTech Global (BHTG) -15%.Fluidigm (FLDM) -14% on Q4 earnings; inks distrib...

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A u...

Kadmon Holdings (KDMN) is down 10.3% post-market after proposing $150M private offering of convertible senior notes due 2027. Initial conversion rate, interest rate and other final terms not yet determined.The company also expects to grant the initial purchaser a 13-day option to pu...

NEW YORK, NY / ACCESSWIRE / February 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced its intent to offer, subject to market conditions and other factors, $150 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") in a private offering to qualifi...

NEW YORK, NY / ACCESSWIRE / February 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of preclinical data demonstrating that KD033, the Company's anti-PD-L1/IL-15 fusion protein, achieved robust anti-tumor responses in multiple syngeneic tumor models. The data we...

Steve Cohen’s Point72 Asset Management reports a 5.3% stake in Kadmon Holdings (KDMN), representing ~9.05M shares.Shares up 5% premarket. For further details see: Kadmon gains 5% after Point72 discloses 5.3% stake

- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively - - cGVHD Key Opinion Leader Webcast Today at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) - NEW YORK, NY / ACCESSWIRE / December 6, 2020 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced 12-mon...